aTyr Pharma reports Q3 2022 cash $79.6M; Phase 3 sarcoidosis study initiated

aTYR PHARMA INC

2022-Q3 EPS reported -$1.34

Ended Q3 2022 with $79.6M in cash, restricted cash, cash equivalents and investments.
First patient dosed in EFZO-FIT Phase 3 study of efzofitimod for pulmonary sarcoidosis; targets 264 subjects.
Will not initiate Phase 1 for ATYR2810 this year; pursuing external non-dilutive funding.
FDA granted Fast Track designation for efzofitimod in systemic sclerosis-associated ILD.
Q3 R&D expenses $9.9M, G&A $3.6M; 29.0M shares outstanding.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

aTYR PHARMA INC reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2022.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0000950170-22-024480

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.